請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47345
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 蘇璧伶 | |
dc.contributor.author | Emerald Chen-Yi Lin | en |
dc.contributor.author | 林澄憶 | zh_TW |
dc.date.accessioned | 2021-06-15T05:55:52Z | - |
dc.date.available | 2013-08-20 | |
dc.date.copyright | 2010-08-20 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-17 | |
dc.identifier.citation | Abdullahi S.U., Mohammed A.A., Trimnell A.R., 1990: Clinical and haematological findings in 70 naturally occurring cases of canine babesiosis. J Small Anim Pract, 31, 145-147.
Bobade P.A., Oduye O.O., Aghomo H.O., 1989: Prevalence of antibodies against Babesia canis in dogs in an endemic area. Rev Elev Med Vet Pays Trop, 42, 211-217. Botros B.A., Moch R.W., Barsoum I.S., 1975: Some observations on experimentally induced infection of dogs with Babesia gibsoni. Am J Vet Res, 36, 293-296. Bourdoiseau G. 2006: Canine babesiosis in France. Vet Parasitol, 138, 118-125. Birkenheuer A.J., Correa M.T., Levy M.G., 2005: Geographic distribution of babesiosis among dogs in the United States and association with dog bites: 150 cases (2000–2003). J Am Vet Med Assoc, 227, 942–947. Birkenheuer A.J., Levy M.G., Breitschwerdt E.B., 2003: Development and evaluation of a seminested PCR for detection and differentiation of Babesia gibsoni (Asian genotype) and B. canis DNA in canine blood samples. J Clin Microbiol, 1, 4172-4177. Birkenheuer A.J., Levy M.G., Savary K.C.M., 1999: Babesia gibsoni infections in dogs from North Carolina. J Am Anim Hosp Assoc 35:125-128. Breitschwerdt E.B., 1990: Babesiosis, pp 796-803. In Greene CE (ed), Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia, PA. Casapulla R., Baldi L., Avallone V., 1998: Canine piroplasmosis due to Babesia gibsoni: clinical and morphological aspects. Vet Rec, 142,168-169. Ceron, J.J., Eckersall, P.D. and Martynez-Subiela S., 2005: Acute phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol, 34, 85–99. Conrad P., Thomford J., Yamane I., 1991: Hemolytic anemia caused by Babesia gibsoni infection in dogs. J Am Vet Med Assoc, 199, 601-605. Criado-Fornelio A., Martinez-Marcos A., Buling-Saraña A., 2003: Molecular studies on Babesia, Theileria and Hepatozoon in southern Europe. Part I. Epizootiological aspects. Vet Parasitol, 113, 189-201. Dantas-Torres F., Figueredo L.A, 2006: Canine babesiosis: a Brazilian perspective. Vet Parasitol, 141, 197-203. Farwell G.E., LeGrand E.K., Cobb C.C., 1982: Clinical observations on Babesia gibsoni and Babesia canis infections in dogs. J Am Vet Med Assoc, 180, 507–511. FÖldvÁri G., Hell E., Farkas R., 2005: Babesia canis from Hungary. Detection by PCR and sequencing. Vet Parasitol, 127, 221-226. Freeman M.J., Kirby B.M., Panciera D.L., 1994. Hypotensive shock syndrome associated with acute Babesia canis infection in a dog. J Am Vet Med Assoc, 204, 94-96. Fukumoto S., Suzuki H., Igarashi I., Xuan X., 2005: Fatal experimental transplacental Babesia gibsoni infections in dogs. Int J Parasitol, 35, 1031–1035. Inokuma H., Okuda M., Yoshizaki Y., 2005: Clinical observations of Babesia gibsoni infection with low parasitemia confirmed by PCR in dogs. Vet Rec, 156, 116-118. Irwin P.J., Hutchinson G.W., 1991: Clinical and pathological findings of Babesia infection in dogs. Aust Vet J, 68, 204-209. Jacobson L.S. 2006: The South African form of severe and complicated canine babesiosis: clinical advances 1994-2004. Vet Parasitol, 138, 126-139. Jacobson L.S., Clark I.A., 1994: The pathophysiology of canine babesiosis: new approaches to an old puzzle. J S Afr Vet Assoc, 65, 134-145. Jefferies R., Ryan U.M., Jardine J., Broughton D.K., Robertson I.D., Irwin P.J., 2007: Blood, bull terriers and babesiosis: further evidence for direct transmission of Babesia gibsoni in dogs. Aust Vet J, 85, 459-463. Köster L.S., Van Schoor M., Goddard A., Thompson P.N., Matjila P.T., Kjelgaard-Hansen M., 2009: C-reactive protein in canine babesiosis caused by Babesia rossi and its association with outcome. J S Afr Vet Assoc, 80, 87-91. Kocan A.A., Kjemtrup A., Meinkoth J., 2001: A genotypically unique Babesia gibsoni-like parasite recovered from a dog in Oklahoma. J Parasitol, 87, 437-438. Lee M.J., Yu D.H., Yoon J.S., Li Y.H., Lee J.H., Chae J.S., ParK J., 2009: Epidemiologic and clinical surveys in dogs infected with Babesia gibsoni in South Korea. Vector Borne Zoonotic Dis, 9, 681-686. Leisewitz A.L., Guthrie A.J., Berry W.L., 1996: Evaluation of the effect of whole-blood transfusion on the oxygen status and acid-base balance of Babesia canis infected dogs using oxygen status algorithm. J S Afr Vet Assoc, 67, 20-26. Lobetti R.G., Möhr B., Dippenaar T., Myburgh E., 2000: A preliminary study on the serum protein response in canine babesiosis. J S Afr Vet Assoc, 71, 38-42. Macintire D.K., Boudreaux M.K., West G.D., 2002: Babesia gibsoni infection among dogs in the southeastern United States. J Am Vet Med Assoc, 220, 325-329. Maronpot R.R., Guindy E., 1970: Preliminary study of Babesia gibsoni (Patton) in wild carnivores and domesticated dogs in Egypt. Am J Vet Res, 31, 797–799. Masuda T., Baba E., Arakawa A., 1983: Relapse of canine babesiosis after prednisolone treatment. Mod Vet Pract, 64, 931-932. Matsuu A., Kawabe A., Koshida Y., 2004: Incidence of Babesia gibsoni infection among Tosa dogs in Aomori prefecture Japan. J Vet Med Sci, 66, 893-897. Matsuu A., Miyamoto K., Ikadai H., Okano S., Higuchi S., 2006: Short report: cloning of the Babesia gibsoni cytochrome B gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment. Am J Trop Med Hyg, 74, 593-597. Matsuu A., Yamasaki M., Xuan X., Ikadai H., Hikasa Y., 2008: In vitro evaluation of the growth inhibitory activities of 15 drugs against Babesia gibsoni (Aomori strain). Vet Parasitol, 157, 1-8. Meinkoth J.H., Kocan A.A., Loud S.D., 2002: Clinical and hematologic effects of experimental infection of dogs with recently identified Babesia gibsoni-like isolates from Oklahoma. J Am Vet Med Assoc, 220, 185-189. Miller D., 1999: The yellow patient, pp 95-97. In Proceedings of a Symposium on Canine Babesiosis and Ehrlichiosis, University of Pretoria, South Africa. Möhr B., Lobetti R.G., Van der Lugt J., 2000: Acute pancreatitis: a rarely recognised complication of canine babesiosis. J S Afr Vet Assoc, 71, 232-239. Moreau Y., Vidor E., Bissuel G., 1989: Vaccination against canine babesiosis: an overview of field observations. Trans R Soc Trop Med Hyg, 83, 95-96. Patton W.S., 1910: Preliminary report on a new piroplasm found in the blood of hounds of the Madras-Hunt and subsequently discovered in the blood of the jackal. Bull Soc Pathol Exot, 3, 274–280. Penzhorn B.L., Lewis B.D., de Waal D.T., 1995: Sterilisation of Babesia canis infections by imidocarb alone or in combination with diminazene. J S Afr Vet Assoc, 66, 157-159. Reiter I., Weiland G., 1989: Recently developed methods for the detection of babesial infections. Trans R Soc Trop Med Hyg, 83, 21-23. Reyers F., Leisewitz A.L., Lobetti R.G., 1998: Canine babesiosis in South Africa: more than one disease. Does this serve as a model for falciparum malaria? Ann Trop Med Parasitol, 92, 503-511. Sakuma M., Setoguchi A., Endo Y., 2009: Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin. J Vet Intern Med, 23, 493-498. Schetters T.H., Kleuskens J., Scholtes N., 1995: Strain variation limits protective activity of vaccines based on soluble Babesia canis antigens. Parasite Immunol, 17, 215-218. Schetters T.P., Kleuskens J.A., Van De Crommert J., De Leeuw P.W., Finizio A.L., Gorenflot A., 2009: Systemic inflammatory responses in dogs experimentally infected with Babesia canis; a haematological study. Vet Parasitol, 162, 7-15 Schetters T.P., Moubri K., Precigout E., 1997. Different Babesia canis isolates, different diseases. Parasitology, 115, 485-493 Scott M.V., Fowler J.L., Ruff M.D., 1970: Babesia gibsoni infection of a dog in Korea. J Am Vet Med Assoc, 159, 1122–1123. Sinha B.P., Ghosh P., 1986: Treatment of clinical cases of canine babesiosis. Indian J Vet Med, 6, 94-97. Song K.H., Kim D.H., Hayasaki M., 2004: The PCR-based detection of Babesia gibsoni infection in dogs (German shepherds) reared in South Korea. Ann Trop Med Parasitol, 98, 149-153. Stegeman J.R., Birkenheuer A.J., Kruger J.M., Breitschwerdt E.B., 2003: Transfusion-associated Babesia gibsoni infection in a dog. J Am Vet Med Assoc, 222, 959-963. Suzuki K., Wakabayashi H., Takahashi M., Fukushima K., Yabuki A., Endo Y., 2007: A Possible treatment strategy and clinical factors to estimate the treatment response in Bebesia gibsoni infection.J Vet Med Sci, 69, 563-568. Taboada J., Harvey J.W., Levy M.G., 1992: Seroprevalence of babesiosis in greyhounds in Florida. J Am Vet Med Assoc, 200, 47-50. Taboada J., Lobetti R., 2006: Babesiosis, pp 722-736. In Greene CE (ed), Infectious diseases of the dog and cat, ed 3. WB Saunders, Philadelphia, PA. Thompson J.P., 1995: Immunologic diseases, pp 2002-2029. In Ettinger SJ, Feldman EC (eds), Textbook of veterinary internal medicine, ed 4. WB Saunders, Philadelphia, PA. Uilenberg G., Franssen F.F.J., Perie N.M., 1989: Three groups of Babesia canis distinguished and a proposal for nomenclature. Vet Q, 11, 33-40. Vercammen F., DeDeken R., Maes L., 1996: Prophylactic treatment of experimental canine babesiosis (Babesia canis) with doxycycline. Vet Parasitol, 66, 251-255 Vercammen F., DeDeken R., Maes L., 1997a: Duration of protective immunity in experimental canine babesiosis after homologous and heterologous challenge. Vet Parasitol, 68, 51-55. Vercammen F., DeDeken R., Maes L., 1997b: Hematological and biochemical profiles in experimental canine babesiosis (Babesia canis). Vlaams Diergeneesk Tijdsch, 66, 174-178. Verdida R.A., Hara O.A., Xuan X., 2004: Serodiagnosis of Babesia gibsoni infection in dogs by an imporved enzyme-linked immunosorbent assay with recombinant truncated P50. J Vet Med Sci, 66, 1517-1521 Wozniak E.J., Barr B.C., Thomford J.W., 1997: Clinical, anatomic, and immunopathologic characterization of Babesia gibsoni infection in the domestic dog (Canis familiaris). J Parasitol, 83, 692–699. Wulansari R., Wijaya A., Ano H., Horii Y., Makimura S., 2003a: Lymphocyte subsets and specific IgG antibody levels in clindamycin-treated and untreated dogs experimentally infected with Babesia gibsoni. J Vet Med Sci, 65, 579-84. Wulansari R., Wijaya A., Ano H., Horii Y., Nasu T., Yamane S., Makimura S., 2003b: Clindamycin in the treatment of Babesia gibsoni infections in dogs. J Am Anim Hosp Assoc, 39, 558-562. Yamane I., Thomford J.W., Gardner I.A., 1993: Evaluation of the indirect fluorescent antibody test for diagnosis of Babesia gibsoni infections in dogs. Am J Vet Res, 54, 1579-1584. Yonamine H., 1979: Condition of dog Babesia, parasitic protozoa, in the prefecture of Okinawa, in Proceedings. 29th Kyushyu Distric Vet Conv, 40. Zahler M., Rinder H., Schein E., 2000a: Detection of a new Babesia microti-like species in dogs. Vet Parasitol, 89, 241-248. Zahler M., Rinder H., Zweygarth E., 2000c: ‘Babesia gibsoni' of dogs from North America and Asia belong to different species. Parasitology, 120, 365-369. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47345 | - |
dc.description.abstract | 犬吉貝氏焦蟲亞洲亞型的感染(Babesia gibsoni,B. gibsoni)之治療長期以來對臨床獸醫師相當具有挑戰性,自從發現對atovaquone具抗藥性的蟲體後,治療B. gibsoni除了合併給予atovaquone以及azithromycin(簡稱AA組)外,研究其他治療策略就顯得非常重要。本研究的目的在於評估合併給予clindamycin phosphate、diminazene aceturate及imidocarb diproprionate(簡稱CDI組)之療效並與AA組的治療效力做比較,進一步分析台灣焦蟲的基因突變情形。本研究將三十隻經由血液抹片檢查(blood smear examination)或聚合酶鏈鎖反應(polymerase chain reaction,PCR)確診為B. gibsoni感染的患犬,依據治療方法不同分為兩組:AA組以atovaquone (13.3mg/Kg body weight,PO,q8h) 與azithromycin (10mg/Kg body weight,PO, q24h)合併治療,CDI組則以clinidamycin phosphate (30mg/kg body weight,PO, q12h)、diminazene aceturate (3.5mg/kg body weight,IM,就診日單次注射) 與 imidocarb diproprionate(6mg/kg body weight,SC,注射完diminazene後隔天單次給予)合併治療。完整紀錄患犬就診當天(day 0)與回診第7、14、21與28天的血紅素(Hb)、血容比(PCV)、紅血球(RBC)、血小板數(platelet counts)與寄生蟲血症(parasitemia),利用巢式多重引子PCR(multiplex-nested PCR,Nested-mPCR)區分B. gibsoni的型別,並定序B. gibsoni cytochrom b(CYTb)基因以觀察突變情形。根據本研究結果,CDI組和AA組有相同的抑制寄生蟲血症與使血液檢查異常恢復的能力,甚至在第28天時,CDI組的Hb、PCV與RBC數值都較AA組高。AA組的復發率(relapse rate)為41.2%然而在CDI組僅15.4%,並且在所有AA組未康復的犬隻中都發現CYTb基因的M121I突變。綜合上述,B. gibsoni在AA組合治療之後確實出現抗藥性,而且CYTb基因的M121I突變與抗藥性的蟲體具絕對相關。因此一旦犬隻復發,則B. gibsoni CYTb基因的定序就顯得相當重要,如果出現了M121I的突變,則需要考量AA組合以外的治療策略。和AA組合相比,CDI組合雖然需要較長的治療時間,但是降低寄生蟲血症的能力相同,且有較高的康復率及所需的花費較少且無明顯的副作用,因此,在臨床治療犬隻B. gibsoni感染上,本研究的發現提供了一個新的選擇。 | zh_TW |
dc.description.abstract | The treatment of Babesia gibsoni Asian genotype (B. gibsoni Asian genotype) has long been a challenge to veterinarians as no drug can be used alone to eliminate the pathogen. Thirty client-owned dogs naturally infected with B. gibsoni as diagnosed with blood smear examination and/or polymerase chain reaction (PCR) were enrolled in this study. Dogs were divided into two groups based on the treatment strategy initially. AA group received atovaquone (13.3mg/Kg body weight, PO, q8h) and azithromycin (10mg/Kg body weight, PO, q24h) and CDI group was treated with clinidamycin phosphate (30mg/kg body weight, PO, q12h), diminazene aceturate (3.5mg/kg body weight, IM, single dose at presenting day) and imidocarb diproprionate(6mg/kg body weight, SC, single dose, the day after diminazene was administrated). PCV, Hb, RBC, platelet counts, and parasitemia were recorded at presenting day (day 0) and during treatment at day 7, 14, 21, and 28. The B. gibsoni 18S rRNA gene was amplified and B. gibsoni cytochrom b (CYTb) gene were sequenced. As compare from the efficacy of suppressing parasitemia and the recovery of hematologic abnormalities, both groups have almost equal efficacy in treating B. gibsoni infection. Values of Hb, PCV, and RBC were higher in CDI group than in AA group at day 28. There were 41.2% dogs in AA group and 15.4% dogs in CDI relapsed after treatment, AA had higher relapsed rate than CDI. M121I mutation in B. gibsoni CYTb gene was detected in all AA-relapse and AA-non-remission samples. Drug resistance do occurred after treating by AA combination and M121I mutation in B. gibsoni CYTb gene is highly correlated in atovaquone-resistant B. gibsoni. Once relapse occurred, screening of the sequence of B. gibsoni CYTb gene is important and an alternative therapeutic strategy should be considered. Compared to AA combination, CDI combination has the same efficacy to suppress parasitemia, a higher recovery rate, and is less expensive without obvious side effects, unless it took longer treatment period. The CDI combination provided a good alternative choice in treating B. gibsoni Asian genotype. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T05:55:52Z (GMT). No. of bitstreams: 1 ntu-99-R97643013-1.pdf: 975104 bytes, checksum: 429191813e7d4b1efd063d2e751ccda6 (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員審定書……………………………………………………… i
致謝………………………………………………………………… ii 摘要………………………………………………………………… iii Abstract…………………………………………………………… v 目錄………………………………………………………………… vii 圖次…………………………………………………………………… x 表次………………………………………………………………… xi 第一章、 文獻探討……………………………………………… 1 第一節、疾病簡介…………………… …………………… 1 第二節、吉貝氏焦蟲之介紹……………………………… 1 2.1 歷史背景及特性…………………………… 1 2.2 流行病學…………………………………… 1 2.3 傳染途徑…………………………………… 3 2.4 致病機轉…………………………………… 3 第三節、臨床特徵………………………………………… 4 3.1 無臨床症狀之感染………………………… 5 第四節、診斷……………………………………………… 5 4.1 臨床病理學………………………………… 5 4.2 血液抹片檢查……………………………… 6 4.3 血清學……………………………………… 7 4.4 聚合酶鏈鎖反應…………………………… 7 第五節、併發症…………………………………………… 8 5.1 黃疸以及肝臟疾病………………………… 8 5.2 免疫性溶解性貧血………………………… 9 第六節、治療與預防……………………………………… 9 6.1 抗焦蟲藥的使用…………………………… 9 6.2 支持療法……………………………… 11 6.3 預防…………………………………… 11 第二章、 序言………………………………………………… 13 第三章、 材料與方法………………………………………… 15 第一節、 動物來源…………………………………………… 15 第二節、 血液檢查…………………………………………… 15 第三節、 治療分組…………………………………………… 16 第四節、 吉貝氏焦蟲檢測………………………………… … 16 4.1 DNA 萃取…………………………………………………… 16 4.2 巢式多重引子聚合酶鏈鎖反應…………………………… 17 4.3 電泳分析………………………………………………………18 第五節、 吉貝氏焦蟲CYTb基因………………………………… 18 5.1 巢式聚合酶鏈鎖反應…………………………………………18 5.2 PCR 產物定序及序列之分析…………………………………18 第六節、 統計分析…………………………………………… 19 第四章、 結果………………………………………………… 20 第一節、 臨床呈相、血液檢查與病例結果…………………… 20 第二節、 吉貝氏焦蟲的分型…………………………………… 22 第三節、 吉貝氏焦蟲CYTb 基因之定序…………………………23 第五章、 討論…………………………………………………… 24 附圖 ……………………………………………………………… 30 附表 ……………………………………………………………… 33 參考文獻 ………………………………………………………… 40 | |
dc.language.iso | zh-TW | |
dc.title | 犬吉貝氏焦蟲亞洲型感染之兩種不同治療策略效果之評估 | zh_TW |
dc.title | Comparison of two different therapeutic strategies in treatment of canine Babesia gibsoni Asian genotype infection | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 闕玲玲,王金和,林中天 | |
dc.subject.keyword | 犬,焦蟲,治療, | zh_TW |
dc.subject.keyword | canine babesiosis,Babesia gibsoni, | en |
dc.relation.page | 46 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-18 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 臨床動物醫學研究所 | zh_TW |
顯示於系所單位: | 臨床動物醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 952.25 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。